Hologic (HOLX)
(Delayed Data from NSDQ)
$73.78 USD
+1.20 (1.65%)
Updated May 31, 2024 04:00 PM ET
After-Market: $73.78 0.00 (0.00%) 7:58 PM ET
2-Buy of 5 2
B Value D Growth D Momentum C VGM
Price, Consensus and EPS Surprise
HOLX 73.78 +1.20(1.65%)
Will HOLX be a Portfolio Killer in June?
Zacks Investment Research is releasing its prediction for HOLX based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for HOLX
Hologic, Inc. (HOLX) Is a Trending Stock: Facts to Know Before Betting on It
Wall Street Analysts Think Hologic (HOLX) Is a Good Investment: Is It?
HOLX: What are Zacks experts saying now?
Zacks Private Portfolio Services
HOLX or EW: Which Is the Better Value Stock Right Now?
Buy 5 Medical Instruments Stocks to Enhance Your Portfolio
Investors Heavily Search Hologic, Inc. (HOLX): Here is What You Need to Know
Other News for HOLX
Hologic Inc. stock outperforms competitors on strong trading day
See How Hologic Ranks Among Analysts' Top Picks With Strong Buyback Activity
Parnassus Mid Cap Fund Q1 2024 Investment Commentary
Hologic recalls BioZorb Marker due to complications with implanted devices
Hologic’s recall of BioZorb Markers classified as FDA’s most serious type